Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet

(Source: InVivoBlog)  proceeds from equity sales or $784 million borrowed in long-term debt deals.  it brings to the table Isis’ antisense oligonucleotide technology (ASO), as well